Skip to main content
lexblog.com/lib/KT4WN8CXviewrecordjson
LEX-WK-KT4WN8CXcrawled 2022-03-03 16:59Z

Switching Study Concludes That Transition From Humira To Samsung Bioepis’s Adalimumab Biosimilar Is Safe and Effective

Emily Rapalino · Big Molecule Watch · Published March 3, 2022

Work details

firm or organization
Goodwin Procter
published
2022-03-03

Citation

Emily Rapalino, Switching Study Concludes That Transition From Humira To Samsung Bioepis’s Adalimumab Biosimilar Is Safe and Effective, Big Molecule Watch (March 3, 2022) [The Library at LexBlog, LEX-WK-KT4WN8CX, lexpid.org/KT4WN8CX]